Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

423 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Model-based prediction of effective target exposure for MEN1611 in combination with trastuzumab in HER2-positive advanced or metastatic breast cancer patients.
Tosca EM, Borella E, Piana C, Bouchene S, Merlino G, Fiascarelli A, Mazzei P, Magni P. Tosca EM, et al. Among authors: merlino g. CPT Pharmacometrics Syst Pharmacol. 2023 Nov;12(11):1626-1639. doi: 10.1002/psp4.12910. Epub 2023 Feb 15. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 36793223 Free PMC article.
MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors.
Merlino G, Fiascarelli A, Bigioni M, Bressan A, Carrisi C, Bellarosa D, Salerno M, Bugianesi R, Manno R, Bernadó Morales C, Arribas J, Dusek RL, Ackroyd JE, Pham PH, Awdew R, Aud D, Trang M, Lynch CM, Terrett J, Wilson KE, Rohlff C, Manzini S, Pellacani A, Binaschi M. Merlino G, et al. Mol Cancer Ther. 2019 Sep;18(9):1533-1543. doi: 10.1158/1535-7163.MCT-18-0624. Epub 2019 Jun 21. Mol Cancer Ther. 2019. PMID: 31227646
[No title available]
[No authors listed] [No authors listed] PMID: 31919082
Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models.
Gaudio E, Tarantelli C, Spriano F, Guidetti F, Sartori G, Bordone R, Arribas AJ, Cascione L, Bigioni M, Merlino G, Fiascarelli A, Bressan A, Adjeiwaa Mensah A, Golino G, Lucchini R, Bernasconi E, Rossi D, Zucca E, Stussi G, Stathis A, Boyd RS, Dusek RL, Bisht A, Attanasio N, Rohlff C, Pellacani A, Binaschi M, Bertoni F. Gaudio E, et al. Among authors: merlino g. Haematologica. 2020 Nov 1;105(11):2584-2591. doi: 10.3324/haematol.2019.227215. Haematologica. 2020. PMID: 33131247 Free PMC article.
Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer.
Fiascarelli A, Merlino G, Capano S, Talucci S, Bisignano D, Bressan A, Bellarosa D, Carrisi C, Paoli A, Bigioni M, Tunici P, Irrissuto C, Salerno M, Arribas J, de Stanchina E, Scaltriti M, Binaschi M. Fiascarelli A, et al. Among authors: merlino g. Breast Cancer Res Treat. 2023 May;199(1):13-23. doi: 10.1007/s10549-023-06895-2. Epub 2023 Mar 13. Breast Cancer Res Treat. 2023. PMID: 36913051 Free PMC article.
Tumor Growth in the High Frequency Medulloblastoma Mouse Model Ptch1+/-/Tis21KO Has a Specific Activation Signature of the PI3K/AKT/mTOR Pathway and Is Counteracted by the PI3K Inhibitor MEN1611.
Ceccarelli M, D'Andrea G, Micheli L, Gentile G, Cavallaro S, Merlino G, Papoff G, Tirone F. Ceccarelli M, et al. Among authors: merlino g. Front Oncol. 2021 Jul 30;11:692053. doi: 10.3389/fonc.2021.692053. eCollection 2021. Front Oncol. 2021. PMID: 34395258 Free PMC article.
The activity of a PI3K δ-sparing inhibitor, MEN1611, in non-small cell lung cancer cells with constitutive activation of the PI3K/AKT/mTOR pathway.
Papoff G, Presutti D, Fustaino V, Parente A, Calandriello C, Alemà S, Scavizzi F, Raspa M, Merlino G, Salerno M, Bigioni M, Binaschi M, Ruberti G. Papoff G, et al. Among authors: merlino g. Front Oncol. 2023 Nov 14;13:1283951. doi: 10.3389/fonc.2023.1283951. eCollection 2023. Front Oncol. 2023. PMID: 38033496 Free PMC article.
423 results